Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
04:35pm, Monday, 10'th Jun 2024
A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
03:56pm, Monday, 10'th Jun 2024
A panel of independent advisors to the FDA recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If approved, Eli L
FDA advisers say Eli Lilly's Alzheimer's treatment is effective
03:47pm, Monday, 10'th Jun 2024
CNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.
7 Over-Hyped Stocks to Sell Before They Plunge: June Edition
03:01pm, Monday, 10'th Jun 2024
Admittedly, bailing on over-hyped stocks to sell can seem like a regretful move in the near-term. Flying in the face of the Wall Street adage “let your winners run,” it's common to feel regretful
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:05am, Monday, 10'th Jun 2024
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz
09:35am, Monday, 10'th Jun 2024
Jared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.
US FDA advisers to review Eli Lilly Alzheimer's drug
07:07am, Monday, 10'th Jun 2024
An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's experimental Alzheimer's drug donanemab.
Eli Lilly's Alzheimer's Drug Donanemab Is Being Considered For FDA Approval—Here's What To Know
06:44am, Monday, 10'th Jun 2024
A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly's experimental Alzheimer's drug donanemab for FDA approval, a closely watched decision that could pave
The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?
10:05am, Saturday, 08'th Jun 2024
Corporations pay large sums to the NBA and WNBA to have their company logos featured as patches on jerseys. This strategy makes sense because it helps brands attract attention from fans watching games
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS , June 8, 2024
Up 400% In 3 Years, Eli Lilly Stock Just Keeps Giving
11:00am, Friday, 07'th Jun 2024
Eli Lilly stock (NYSE: LLY) has seen phenomenal gains of 400% from levels of $170 in early 2021 to around $840 now. This reflects a meaningful outperformance compared to some of its peers, with Pfizer
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
05:45am, Friday, 07'th Jun 2024
Eli Lilly's weight loss drugs have helped revenue and the stock price to soar in recent times. Demand is so high that Lilly and rival Novo Nordisk have ramped up manufacturing to try to address it.
Google parent Alphabet taps Eli Lilly exec as new CFO
03:03pm, Thursday, 06'th Jun 2024
Google parent company Alphabet Inc (NASDAQ:GOOG) has appointed its new finance chief after nearly a year-long search. Taking over the role of chief financial officer is Anat Ashkenazi, who joins the
Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO
11:26am, Thursday, 06'th Jun 2024
Eli Lilly and Company LLY announced that its executive vice president and chief financial officer (CFO) Anat Ashkenazi has resigned after serving for 23 years at the company. Ashkenazi has joined Goo
US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug
09:39am, Thursday, 06'th Jun 2024
A panel of outside experts to the U.S. health regulator will vote on Monday on whether data for Eli Lilly's experimental treatment, donanemab, shows it is effective for treating patients with early Al
